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ABSTRACT 
Signal-induced proliferation-associated protein 1 (SIPA1) is known to be a GTPase 
activating protein. Overexpressed SIPA1 is related to metastatic progression in breast and 
prostate cancers; however, the relevance of SIPA1 in oral squamous cell carcinoma 
(OSCC) is still unknown. The aim of this study was to examine SIPA1 expression and its 
functional mechanisms in OSCC. SIPA1 mRNA and protein expressions were analyzed 
by quantitative reverse transcriptase-polymerase chain reaction, Western blot, and 
immunohistochemistry. The expressions of SIPA1 were up-regulated significantly in vitro 
and in vivo. Moreover, SIPA1 expression was correlated with regional lymph node 
metastasis. We next assessed the cellular functions associated with tumoral metastasis 
using SIPA1 knockdown (shSIPA1) cells and analyzed the downstream molecules of 
SIPA1, i.e., bromodomain containing protein 4, integrin beta1 (ITGB1), and matrix 
metalloproteinase 7 (MMP7). The shSIPA1 cells showed decreased invasiveness and 
migratory activities, however cellular adhesion ability was maintained at a high level. In 
addition, ITGB1 expression was greater in shSIPA1 cells, whereas MMP7 expression was 
lower than in control cells. This research is the first to establish that SIPA1 promotes 
cancer metastasis by regulating the ITGB1 and MMP7.Therefore, SIPA1 might be a novel 
therapeutic target for patients with lymph node metastasis of OSCC.  
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1. Introduction 
Signal-induced proliferation associated protein 1 (SIPA1), a GTPase activating 
protein, was discovered in proliferating lymphocytes as mitogen-induced nuclear protein 
[1]. SIPA1 promotes catalyzation of hydrolyze Rap1GTP/GDP and is known to be a 
negative regulator of Ras-related protein [2], which transduces the signals for various 
cellular functions, including development, cellular proliferation, and cellular adhesion [3-
7]. 
SIPA1 and Rap1 interaction is related to leukemia. In addition, the interaction 
controls cellular adhesion in cancer metastasis [5]. SIPA1 links the metastatic predictive 
gene expression and signaling for cellular adhesion [5]. Overexpression of SIPA1 was 
found in several types of cancers, such as colon, prostate, and breast cancers [2, 8, 9]. 
Knockdown experiments have shown that SIPA1 is related closely to cellular adhesion 
and controls ECM-related genes [9]. In contrast, SIPA1-deficient mice developed myeloid 
disorders that resembled chronic myelogenous leukemia [10]. Therefore, SIPA1 plays 
pivotal roles in cancer development and progression. Cancer metastasis induces a 
recurrence and decreases the survival rates of the patients all over the world. The 
exploring of cancer metastasis mechanism is a crucial role to improve biomedical 
treatment and develop novel therapeutics. 
This is a first study that we demonstrate the mechanism of cancer progression and 
metastasis in OSCC. In this experiment, we showed that SIPA1 promotes regional lymph 
node metastasis of OSCC by controlling cellular invasion and migration. Therefore, 
SIPA1 might be a novel biomarker of metastasis of OSCCs. 
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2. Materials and methods 
2.1. The statement of ethics 
The ethical committee of Chiba University (protcol number, 236) approved the 
protocol of the present study. Prior participating in our study, all patients were provided 
informed consent. 
 
2.2. Cells and clinical OSCC tissue samples 
The nine cell lines from human OSCC , HSC-2, HSC-3, HSC-4, Sa3, Ca9-22, SAS, 
KOSC-2, Ho-1-u-1, and Ho-1-N-1, were purchased from RIKEN BioResource Center 
(Ibaraki, Japan) and JCRB Cell Bank (Osaka Japan). We obtained human normal oral 
keratinocytes (HNOKs) from young healthy patients and cultured as described previously 
[11, 12]. In this research, HNOKs was used as a normal control [11-14]. 
105 clinical OSCC tissue samples and normal oral mucosa samples (patient-
matched) were obtained at the Department of Dentistry and Oral-Maxillofacial Surgery, 
Chiba University Hospital. Tissue samples were formalin-fixed for pathological diagnosis 
and immunohistochemistry (IHC). Each OSCC sample was performed histopathological 
diagnosis according to the WHO criteria at the Department of Pathology of Chiba 
University Hospital [15]. The clinical stages of the OSCCs were determined based on the 
TNM classification [16]. 
 
2.3. cDNA synthesis and protein extraction  
RNA and protein were isolated as described previously [11]. We isolated 
cytoplasmic and nuclear fractions by NE-PER Nuclear and Cytoplasmic Extraction 
reagents (Thermo Fisher Scientific, Rockford, IL, USA). 
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2.4. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) 
qRT-PCR was conducted to evaluate the expression levels of target mRNAs using 
the FastStart Essential DNA Probes Master (Roche Diagnostics, Mannheim, Germany) on 
the LightCycler 480 Instrument II (Roche Diagnostics, Switzerland). Primers and 
universal probes (designed by Universal Probe Library) were used as follows: SIPA1 
forward, 5′-ACCTTGTCTCTG CGGAAC TC-3′ and reverse, 5′-GTCCTC CAG 
GGTCCCACT-3′ (probe #18), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
forward, 5′-AGCCACATCGCTCAGACAC-3′ and reverse, 5′- 
GCCCAATACGACCAAATCC-3′ (probe #60), integrin beta1 (ITGB1) forward, 5′-
CGATGCCATCATGCAAGT-3′ and reverse, 5′-ACACCAGCAGCCGTGTAAC-3′ 
(probe #65), and matrix metalloproteinase 7 (MMP7) forward, 5′- 
TGGACGGATGGTAGCAGTCT-3′ and reverse, 5′- TCTCCATTTCCATAGGTTGGAT-
3′ (probe #6). The amounts of target and control transcripts were estimated from the 
respective standard curves. The values were normalized according to the level of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the endogenous control. 
 
2.5. Western blot analysis 
Western blot analysis was performed as described previously [11]. The membranes 
were incubated with anti-SIPA1 rabbit monoclonal antibody (dilute concentration 1:3000, 
Abcam, Cambridge, UK, ab189929), anti-GAPDH mouse monoclonal antibody (dilute 
concentration 1:200, Santa Cruz Biotechnology, Dallas, TX, USA, sc-32233), anti-
bromodomain containing protein 4 (BRD4) rabbit monoclonal antibody (dilute 
concentration 1:1000, Abcam, ab128874), anti-lamin A/C rabbit polyclonal antibody 
(dilute concentration 1:200, Santa Cruz Biotechnology, sc-20681), anti-ITG1 rabbit 
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monoclonal antibody (dilute concentration 1:10000, Abcam, ab52971), and anti-MMP7 
rabbit monoclonal antibody (dilute concentration 1:1000, Abcam, ab205525). 
2.6. Immunohistochemistry (IHC) 
IHC was carried out as described previously [17-20]. We used the free software, 
IHC Profiler for IHC scoring (https://sourceforge.net/projects/ihcprofiler/) [21]. The 
SIPA1 IHC scores were calculated combining the proportion of SIPA1 stained cells and 
the staining intensity. The intensity of the stained cells was classified four levels: 0 (none 
staining); 1 (weak staining); 2 (moderate staining); and 3 (strong staining). In order to 
determine the cutoff points of the SIPA1 IHC scores for each clinical classification, we 
analyzed all scores of 105 OSCC patients using receiver operating characteristic ( ROC) 
curve analysis. Independent pathologists who belong to Chiba University Hospital 
evaluated the degree of immunostaining. 
 
2.7. Transfection of shRNA plasmid 
SIPA1 shRNA plasmid (shSIPA1) (Santa Cruz Biotechnology, sc-45418-SH) or 
control shRNA plasmid (shMock) (Santa Cruz Biotechnology, sc-108060) were 
transfected into two OSCC cells (HSC-3 and HSC-4) using Lipofectamine 3000 
(Invitrogen) as described previously [14]. The stable transfected cells were isolated in a 
culture medium containing puromycin (1 µg/ml) (Santa Cruz Biotechnology). To evaluate 
the knockdown efficiency of SIPA1, we conducted qRT-PCR and Western blot analyses. 
 
2.8. Cellular proliferation assay 
To examine the effect of SIPA1 knockdown on cellular proliferation, we performed 
the cell proliferation assay as described previously [19]. 
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2.9. Cellular invasion assay  
To examine the effect of SIPA1 knockdown on cellular invasion, the cells (2.5×10
5
) 
were seeded on Corning® BioCoat™ Matrigel® invasion chamber with 8.0μm PET 
Membrane 6 well plates (Corning, NY,USA, product #354481). The cellular invasion 
assay was performed, as described previously [22-25].  
 
2.10. Cellular migration assay  
To investigate the effect of SIPA1 knockdown on cellular migration, cells were 
plated in 6 well culture plates in DMEM containing 10% FBS and cultured until a 
confluent. The cell migration assay was performed as described previously [22-25]. The 
wound area was monitored at every 12 hours for 24 hours.  
 
2.11. Cellular adhesion assay 
The adhesion assay was performed as described previously [26], to assess the 
cellular adhesiveness of shSIPA1 cell and shMock cells. The numbers of stained adherent 
cells were observed and counted by a light microscope at ×200 magnification in five 
random fields.  
 
2.12. Statistical analysis 
Statistical differences were analysed by the χ2 test, Student’s t-test, Fisher’s exact 
test, and Mann-Whitney U-test. Statistical significant was indicated with asterisk on the 
figures. All data are expressed as the mean ± the standard error of the mean. 
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3. Results 
3.1. Up-regulation of SIPA1 in OSCC cells 
To assess the expression status of SIPA1, we conducted qRT-PCR and Western blot 
analyses using nine OSCC cells and the HNOKs. The both analyses showed that SIPA1 
expressions were increased significantly in all nine OSCC cells compared with the 
HNOKs (P<0.05) (Fig. 1A, 1B). 
 
3.2. Evaluation of SIPA1 expression in primary OSCCs 
Representative IHC data of SIPA1 in adjacent normal oral tissue and primary OSCC 
tissue were shown in Fig. 2A and B. We found that SIPA1expression was markedly up-
regulated in the cytosol of the OSCC specimens. However, normal tissues were seen 
almost negative immunostaining. Using the IHC scoring system, the SIPA1 IHC scores in 
the OSCCs ranged from 60 to 290 (median, 120) and adjacent normal oral tissues ranged 
from 13 to 105 (median, 60), a difference that reached significance (P<0.05) (Fig. 2C). 
The area under the curve (AUC) of the ROC curve analysis was 0.713, and the cutoff 
value was 110.0 in the analysis of the regional lymph node metastasis (Fig. 2D). 
Representative IHC data of SIPA1 protein in the regional lymph node metastasis of 
primary OSCCs were shown in Fig. 2E. 
 
3.3. Establishment of SIPA1 knockdown cells 
To investigate SIPA1 expression levels in shSIPA1 cells, qRT-PCR and Western blot 
analyses were conducted (Fig. 3A, B, respectively).The both analyses showed that SIPA1 
expression was markedly (P<0.05) down-regulated in shSIPA1 cells compared with 
control cells (shMock) (Fig. 3A, 3B).  
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3.4. Cellular functional analyses of SIPA1 knockdown cells 
In order to assess the cellular functions of SIPA1 knockdown cells, we examined 
cellular proliferation, invasion, migration, and adhesion assays. Regarding cellular 
proliferation, there was no significant difference of cell growth ability between shSIPA1 
cells and control cells (shMock) (Fig. 4A). The number of penetrating shSIPA1 cells 
clearly decreased compared with shMock cells (P<0.05) (Fig. 4B). Regarding the 
migration assay, the area which was wounded by a micropipette tip decreased obviously in 
shMock cells after 24 hours (P<0.05). In contrast, the gap was still remained in shSIPA1 
cells over 24 hours (Fig. 4C). The number of adhering cells markedly increased in 
shSIPA1 cells compared with shMock cells (P<0.05) (Fig. 4D).  
 
3.5. BRD4 expression in SIPA1 knockdown cells 
Because a previous study showed that SIPA1 interacts directly with a chromatin 
adaptor, BRD4 [27], we performed Western blot analysis to examine BRD4 expression of 
the nuclear and cytosolic fractions in shSIPA1 and shMock cells. Abundant BRD4 protein 
expression in the nuclear fraction of the shSIPA1 cells was seen compared with shMock 
cells (P<0.05) (Fig. 5). 
 
3.6. ITGB1 and MMP7 expression levels in SIPA1 knockdown cells 
BRD4 regulates a series of ECM-related gene expression in mammary tumoral cells 
[28]. When we investigated ITGB1 and MMP7, the expressions of ITGB1 in shSIPA1 
cells were markedly higher than in shMock cells (P<0.05) (Fig. 6A, B), whereas the 
expression of MMP7 in shSIPA1 cells was significantly lower than in control cells 
(P<0.05) (Fig. 6C, D). 
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3.7. Correlations between SIPA1 expressions and clinicopathological characteristics 
The correlations between the status of SIPA1 protein expressions and the 
clinicopathological characteristics of the patients with OSCC using the IHC scoring 
system were exhibited in Table 1. Among the clinical classifications, the SIPA1-positive 
OSCCs were correlated with regional lymph node metastasis. (P<0.05) 
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4. Discussion 
Our study found that SIPA1 was up-regulated in OSCC cells and primary OSCCs 
compared with the normal counterparts. Moreover, higher SIPA1 expression was markedly 
(P<0.05) related to regional lymph node metastasis (Table 1). Therefore, SIPA1 
overexpression might be linked to OSCC invasiveness and migration and have a crucial 
role in OSCC metastasis.  
Preventing metastasis of cancer is an important factor to improve biomedical 
treatment all over the world. The prognosis in advanced OSCC is poor and the 5-year 
survival rate in patients with OSCC is about 50% [29, 30]. The 5-year survival rate of 
OSCC is 90% in patients without regional lymph node metastasis but less than 40% in 
patients with regional lymph node metastasis, suggesting that metastasis is one of the most 
important prognostic factors [31-36]. In addition to the current study, IHC from the 
patients with prostate cancers and SIPA1 overexpression or knockdown experiments 
found a positive correlation between SIPA1 expression and tumor metastasis [9].  
SIPA1 interacts with chromatin-binding protein, BRD4, to modulate the enzymatic 
activity against Rap1GTP, which mediates the ECM-related gene expression and affects 
cancer metastasis but not cellular proliferation rates [9]. Since SIPA1 promoted metastasis 
of several cancer cells by inhibiting the adhesion ability and down-regulated the 
expression of ECM-related genes [9], we speculated that the downstream molecules of the 
SIPA1/BRD4 interaction have crucial roles in OSCC metastasis. Some reports including 
our previous study showed that integrin and MMPs regulated tumoral metastasis in several 
types of cancers [37-41]. Consistent with this hypothesis, we found that SIPA1 
knockdown cells showed high ITGB1 expression and low MMP7 expression in OSCC 
(Fig. 6), indicating that these two molecules might modulate oral cancer metastasis. 
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MMPs (MMP2, 7, and 9) have been implicated in tumoral invasion and metastasis and 
tumoral initiation and growth [42]. Of them, MMP7 expression at the invasive front was 
detected in 50% of cancer tissues and was associated with the depth of invasiveness [37]. 
There were no evident differences of MMP2 and MMP9 between shSIPA1 cells and 
control cells in the current study (data not shown), suggesting that the SIPA1/BRD4 
interaction in OSCC might directly control MMP7 expression not MMP2 and 9. 
Therefore, more researches are needed to better understand the target molecules of the 
SIPA1/BRD4 interaction.  
In conclusion, this study is the first to establish that SIPA1 plays a crucial role in 
metastatic progression in OSCC by controlled expression of ITGB1 and MMP7 through 
the SIPA1/BRD4 interaction. These altered expressions promoted environmental changes 
in cellular invasion, migratory, and adhesion abilities. Thus, our data suggested that SIPA1 
might be a potential biomarker of cancer metastasis and a novel therapeutic target in 
OSCC. 
 
 
 
 
Conflict of Interest Disclosures 
The authors have declared that no competing interests exist. 
 
Acknowledgments 
We thank Ms. Lynda C. Charters for editing this manuscript. The authors received no 
financial support.  
13 
 
References 
[1]  M. Hattori, N. Tsukamoto, M.S. Nur-e-Kamal, B. Rubinfeld, K. Iwai, H. Kubota, H.  
          Maruta, N. Minato, Molecular cloning of a novel mitogen-inducible nuclear protein    
          with a Ran GTPase-activating domain that affects cell cycle progression, Mol. Cell.    
          Biol. 15 (1995) 552–60. PMID: 7799964 ,PMCID: PMC232010 
[2] K. Ji, L. Ye, A.M. Toms, R. Hargest, T.A. Martin, F. Ruge, J. Ji, W.G. Jiang, 
Expression of signal-induced proliferation-associated gene 1 (SIPA1), a 
RapGTPase-activating protein, is increased in colorectal cancer and has diverse 
effects on functions of colorectal cancer cells, Cancer Genomics and Proteomics. 
9 (2012) 321–328. 
[3] J.L. Bos, Linking Rap to cell adhesion, Curr. Opin. Cell Biol. 17 (2005) 123–128. 
doi:10.1016/j.ceb.2005.02.009 PMID: 15780587 
[4] K. Kometani, D. Ishida, M. Hattori, N. Minato, Rap1 and SPA-1 in hematologic 
malignancy, Trends Mol. Med. 10 (2004) 401–408. 
doi:10.1016/j.molmed.2004.06.004. PMID: 15310461 
[5] N. Minato, M. Hattori, Spa-1 (Sipa1) and rap signaling in leukemia and cancer 
metastasis, Cancer Sci. 100 (2009) 17–23. doi:10.1111/j.1349-
7006.2008.01011.x. PMID: 19037996 
[6] M. Hattori, N. Minato, Rap1 GTPase: Functions, Regulation, and Malignancy, J. 
Biochem. 134 (2003) 479–484. doi:10.1093/jb/mvg180. PMID: 14607972 
[7] J.L. Bos, J. de Rooij, K. a Reedquist, Rap1 signalling: adhering to new models, 
Nat. Rev. Mol. Cell Biol. 2 (2001) 369–377. doi:10.1038/35073073. PMID: 
11331911 
[8] Y. Zhang, Y. Gong, D. Hu, P. Zhu, N. Wang, Q. Zhang, M. Wang, a Aldeewan, 
H. Xia, X. Qu, B.Z. Ring, N. Minato, L. Su, Nuclear SIPA1 activates integrin β1 
promoter and promotes invasion of breast cancer cells, Oncogene. (2014) 1–12. 
doi:10.1038/onc.2014.36. PMID: 24704834 
[9] Y. Shimizu, Y. Hamazaki, M. Hattori, K. Doi, N. Terada, T. Kobayashi, Y. Toda, 
T. Yamasaki, T. Inoue, Y. Kajita, A. Maeno, T. Kamba, Y. Mikami, T. Kamoto, 
T. Yamada, T. Kanno, K. Yoshikawa, O. Ogawa, N. Minato, E. Nakamura, SPA-
1 controls the invasion and metastasis of human prostate cancer, Cancer Sci. 102 
(2011) 828–836. doi:10.1111/j.1349-7006.2011.01876.x. PMID: 21251160 
[10] D. Ishida, K. Kometani, H. Yang, K. Kakugawa, K. Masuda, K. Iwai, M. Suzuki, 
S. Itohara, T. Nakahata, H. Hiai, H. Kawamoto, M. Hattori, N. Minato, 
Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-
deficient mice, Cancer Cell. 4 (2003) 55–65. doi:10.1016/S1535-6108(03)00163-
6. PMID: 12892713 
14 
 
[11] Y. Endo, K. Uzawa, Y. Mochida, M. Shiiba, H. Bukawa, H. Yokoe, H. Tanzawa, 
Sarcoendoplasmic reticulum Ca(2+) ATPase type 2 downregulated in human oral 
squamous cell carcinoma, Int. J. Cancer. 231 (2004) 225–231. 
doi:10.1002/ijc.20118. PMID: 15069686 
[12]  Kasamatsu A, Uzawa K, Nakashima D, Koike H, Shiiba M, Bukawa H, et al.    
      Galectin-9 as a regulator of cellular adhesion in human oral squamous cell   
       carcinoma cell lines, Int J Mol Med. 2005;16(2):269-73. PMID: 16012760 
[13] T. Koyama, K. Ogawara, A. Kasamatsu, A. Okamoto, H. Kasama, Y. Minakawa, 
K. Shimada, H. Yokoe, M. Shiiba, H. Tanzawa, K. Uzawa, ANGPTL3 is a novel 
biomarker as it activates ERK/MAPK pathway in oral cancer, Cancer Med. 4 
(2015) 759–769. doi:10.1002/cam4.418. PMID: 25644496 PMCID: 
PMC4430268 
[14] I. Miyamoto, A. Kasamatsu, M. Yamatoji, D. Nakashima, K. Saito, M. Higo, Y. 
Endo-Sakamoto, M. Shiiba, H. Tanzawa, K. Uzawa, Kinesin family member 14 
in human oral cancer: A potential biomarker for tumoral growth, Biochem. 
Biophys. Reports. 3 (2015) 26–31. doi:10.1016/j.bbrep.2015.07.008. 
[15] J.J. Pindborg, P. a. Reichart, C.J. Smith, I. van der Waal, World Health 
Organization: Histological Typing of Cancer and Precancer of the Oral Mucosa. 
Second Edition, Springer-Verlag. 2 (1997). doi:10.1007/978-3-642-60592-5. 
[16] LH S, MK G, C W. UICC TNM classification of Malignant tumors. 2009. 
[17] K. Usukura, A. Kasamatsu, A. Okamoto, Y. Kouzu, M. Higo, H. Koike, Y. 
Sakamoto, K. Ogawara, M. Shiiba, H. Tanzawa, K. Uzawa, Tripeptidyl peptidase 
II in human oral squamous cell carcinoma, J. Cancer Res. Clin. Oncol. 139 
(2013) 123–130. doi:10.1007/s00432-012-1307-y. PMID: 22986808 
[18] Y. Minakawa, A. Kasamatsu, H. Koike, M. Higo, D. Nakashima, Y. Kouzu, Y. 
Sakamoto, K. Ogawara, M. Shiiba, H. Tanzawa, K. Uzawa, Kinesin family 
member 4A: A potential predictor for progression of human oral cancer, PLoS 
One. 8 (2013) 1–8. doi:10.1371/journal.pone.0085951. PMID: 24386490 
PMCID: PMC3875575 
[19] T. Baba, Y. Sakamoto, A. Kasamatsu, Y. Minakawa, S. Yokota, M. Higo, H. 
Yokoe, K. Ogawara, M. Shiiba, H. Tanzawa, K. Uzawa, Persephin: A potential 
key component in human oral cancer progression through the RET receptor 
tyrosine kinase-mitogen-activated protein kinase signaling pathway, Mol. 
Carcinog. 617 (2013) 1–8. doi:10.1002/mc.22127. PMID: 24375483 
[20] K. Uzawa, A. Kasamatsu, T. Saito, T. Takahara, Y. Minakawa, K. Koike, M. 
Yamatoji, D. Nakashima, M. Higo, Y. Sakamoto, M. Shiiba, H. Tanzawa, Long-
term culture of human odontoma-derived cells with a Rho kinase inhibitor, Exp. 
Cell Res. 347 (2016) 232–240. doi:10.1016/j.yexcr.2016.08.005. PMID: 
27514999 
15 
 
[21] F. Varghese, A.B. Bukhari, R. Malhotra, A. De, IHC profiler: An open source 
plugin for the quantitative evaluation and automated scoring of 
immunohistochemistry images of human tissue samples, PLoS One. 9 (2014). 
doi:10.1371/journal.pone.0096801. PMID: 24802416 PMCID: PMC4011881 
[22] T. Saito, A. Kasamatsu, K. Ogawara, I. Miyamoto, K. Saito, M. Iyoda, T. Suzuki, 
Y. Endo-Sakamoto, M. Shiiba, H. Tanzawa, K. Uzawa, Semaphorin7A 
promotion of tumoral growth and metastasis in human oral cancer by regulation 
of g1 cell cycle and matrix metalloproteases: Possible contribution to tumoral 
angiogenesis, PLoS One. 10 (2015) 1–20. doi:10.1371/journal.pone.0137923. 
PMID: 26378920 PMCID: PMC4574527 
[23] Y. Saito, A. Kasamatsu, A. Yamamoto, T. Shimizu, H. Yokoe, Y. Sakamoto, K. 
Ogawara, M. Shiiba, H. Tanzawa, K. Uzawa, ALY as a potential contributor to 
metastasis in human oral squamous cell carcinoma, J. Cancer Res. Clin. Oncol. 
139 (2013) 585–594. doi:10.1007/s00432-012-1361-5. PMID: 23242234 
[24] S. Ishige, A. Kasamatsu, K. Ogoshi, Y. Saito, K. Usukura, H. Yokoe, Y. Kouzu, 
H. Koike, Y. Sakamoto, K. Ogawara, M. Shiiba, H. Tanzawa, K. Uzawa, 
Decreased expression of kallikrein-related peptidase 13: Possible contribution to 
metastasis of human oral cancer, Mol. Carcinog. 53 (2014) 557–565. 
doi:10.1002/mc.22007. PMID: 23371469 
[25] R. Kimura, A. Kasamatsu, T. Koyama, C. Fukumoto, Y. Kouzu, M. Higo, Y. 
Endo-Sakamoto, K. Ogawara, M. Shiiba, H. Tanzawa, K. Uzawa, Glutamate acid 
decarboxylase 1 promotes metastasis of human oral cancer by beta-catenin 
translocation and MMP7 activation, BMC Cancer. 13 (2013) 555. 
doi:10.1186/1471-2407-13-555. PMID: 24261884 PMCID: PMC3866561 
[26] M. Yamatoji, A. Kasamatsu, Y. Kouzu, H. Koike, Y. Sakamoto, K. Ogawara, M. 
Shiiba, H. Tanzawa, K. Uzawa, Dermatopontin: A potential predictor for 
metastasis of human oral cancer, Int. J. Cancer. 130 (2012) 2903–2911. 
doi:10.1002/ijc.26328. PMID: 21796630 
[27] A. Farina, M. Hattori, J. Qin, Y. Nakatani, N. Minato, K. Ozato, Bromodomain 
protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and 
subcellular localization, Mol. Cell. Biol. 24 (2004) 9059–69. 
doi:10.1128/MCB.24.20.9059-9069.2004. PMID: 15456879 PMCID: 
PMC517877 
[28] N.P.S. Crawford, J. Alsarraj, L. Lukes, R.C. Walker, J.S. Officewala, H.H. Yang, 
M.P. Lee, K. Ozato, K.W. Hunter, Bromodomain 4 activation predicts breast 
cancer survival, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 6380–6385. 
doi:10.1073/pnas.0710331105. PMID: 18427120 PMCID: PMC2359777 
[29] D.M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002, CA. 
Cancer J. Clin. 55 (2002) 74–108. doi:10.3322/canjclin.55.2.74. 
16 
 
[30] A Mashberg, P. Boffetta, R. Winkelman, L. Garfinkel, Tobacco smoking, alcohol 
drinking, and cancer of the oral cavity and oropharynx among U.S. veterans, 
Cancer. 72 (1993) 1369–75. doi:10.1002/1097-0142(19930815)72:4<1369::AID-
CNCR2820720436>3.0.CO;2-L. PMID: 8339227 
[31] G.J. Macfarlane, T. Zheng, J.R. Marshall, P. Boffetta, S. Niu, J. Brasure, F. 
Merletti, P. Boyle, Alcohol, tobacco, diet and the risk of oral cancer: a pooled 
analysis of three case-control studies, Oral Oncol. Eur J Cancer. 31B (1995) 181–
187. PMID: 7549758 
[32] E.R. Fearon, B. Vogelstein, A genetic model for colorectal tumorigenesis, Cell. 
61 (1990) 759–767. doi:10.1016/0092-8674(90)90186-I. PMID: 2188735 
[33] C.J. Marshall, Tumor suppressor genes, Cell. 64 (1991) 313–326. 
doi:10.1016/0092-8674(91)90641-B. PMID: 1988150 
[34] D.S. Gokhin, V.M. Fowler, Tropomodulin capping of actin filaments in striated 
muscle development and physiology, J. Biomed. Biotechnol. 2011 (2011). 
doi:10.1155/2011/103069. PMID: 22013379 
[35] S. Yamashiro, D.S. Gokhin, S. Kimura, R.B. Nowak, V.M. Fowler, 
Tropomodulins: Pointed-end capping proteins that regulate actin filament 
architecture in diverse cell types, Cytoskeleton. 69 (2012) 337–370. 
doi:10.1002/cm.21031. PMID: 22488942 PMCID: PMC3444156  
[36] K.T. Bliss, T. Tsukada, S.M. Novak, M. V. Dorovkov, S.P. Shah, C. Nworu, A.S. 
Kostyukova, C.C. Gregorio, Phosphorylation of tropomodulin1 contributes to the 
regulation of actin filament architecture in cardiac muscle, FASEB J. 28 (2014) 
3987–3995. doi:10.1096/fj.13-246009. PMID: 24891520 PMCID: PMC4139905 
[37] H. Yamamoto, Y. Adachi, F. Itoh, S. Iku, K. Matsuno, M. Kusano, Y. Arimura, T. 
Endo, Y. Hinoda, M. Hosokawa, K. Imai, Association of matrilysin expression 
with recurrence and poor prognosis in human esophageal squamous cell 
carcinoma, Cancer Res. 59 (1999) 3313–6. PMID: 10416584  
[38] A. Senota, F. Itoh, H. Yamamoto, Y. Adachi, Y. Hinoda, K. Imai, Relation of 
matrilysin messenger RNA expression with invasive activity in human gastric 
cancer, Clin. Exp. Metastasis. 16 (1998) 313–21. 
http://www.ncbi.nlm.nih.gov/pubmed/9626810. PMID: 9626810 
[39] H. Kouro, S. Kon, N. Matsumoto, T. Miyashita, A. Kakuchi, D. Ashitomi, K. 
Saitoh, T. Nakatsuru, S. Togi, R. Muromoto, T. Matsuda, The novel α4B 
murine α4 Integrin protein splicing variant inhibits α4 protein-dependent cell 
adhesion, J. Biol. Chem. 289 (2014) 16389–16398. 
doi:10.1074/jbc.M114.553610. PMID: 24755217 PMCID: PMC4047406 
[40] A. Varzavand, W. Hacker, D. Ma, K.N. Gibson-Corley, M. Hawayek, O.J. Tayh, 
J.A. Brown, M.D. Henry, C.S. Stipp, α3β1 Integrin suppresses prostate cancer 
17 
 
metastasis via regulation of the Hippo pathway, 2016. doi:10.1158/0008-
5472.CAN-16-1483. PMID: 27680681 
[41] A. Yamamoto, A. Kasamatsu, S. Ishige, K. Koike, K. Saito, Y. Kouzu, H. Koike, 
Y. Sakamoto, K. Ogawara, M. Shiiba, H. Tanzawa, K. Uzawa, Exocyst complex 
component Sec8: A presumed component in the progression of human oral 
squamous-cell carcinoma by secretion of matrix metalloproteinases, J. Cancer 
Res. Clin. Oncol. 139 (2013) 533–542. doi:10.1007/s00432-012-1356-2. PMID: 
23207790 
[42]   M. Egeblad, Z. Werb, New functions for the matrix metalloproteinases in cancer 
progression, Nat Rev Cancer. 2 (2002) 161–174. doi:10.1038/nrc745. PMID: 
11990853 
 
  
18 
 
Legends 
Fig. 1. Up-regulation of SIPA1 expression in OSCC-derived cell lines. (A) Quantification 
of SIPA1 mRNA expression in OSCC-derived cell lines by qRT-PCR analysis. Significant 
(✽P<0.05, Student’s t-test) up-regulation of SIPA1 mRNA is seen in nine OSCC-derived 
cell lines compared with the HNOKs. Data are expressed as the mean ± SEM of triplicate 
results. (B) Western blot analysis of SIPA1 protein in OSCC-derived cell lines and 
HNOKs. SIPA1 protein expression is up-regulated in OSCC-derived cell lines compared 
with the HNOKs. Densitometric SIPA1 protein data are normalized to the GAPDH protein 
levels. The values are expressed as a percentage of the HNOKs. 
 
Fig. 2. Evaluation of SIPA1 expression in primary OSCCs. (A) Representative IHC results 
of SIPA1 protein in normal oral tissue and (B) primary OSCC (original magnification, 
×100. Scale bars, 100 μm). (C) The status of SIPA1 protein expression in primary OSCCs 
(n=105) and normal counterparts based on the IHC scoring system. The SIPA1 IHC scores 
of OSCCs and normal oral tissues range from 60 to 290 (median, 120) and 13 to 105 
(median, 60), respectively. SIPA1 protein expression levels in OSCCs are markedly 
(*P<0.05, Student’s t-test) higher than in normal oral tissues. (D) ROC curve analysis 
showed the optimal cutoff point, 110.0 (AUC, 0.713) in analysis of the regional lymph 
node. (E) Representative IHC results of SIPA1 protein in the regional lymph nodes of 
primary OSCCs (original magnification, ×100 and ×200. Scale bars, 100 μm). 
 
Fig. 3. Establishment of SIPA1 knockdown cells. (A) Expression of SIPA1 mRNA in 
shMock and shSIPA1 cells (HSC-3 and HSC-4 derived transfectants). SIPA1 mRNA 
expression in shSIPA1 cells is significantly (✽P<0.05, Student’s t-test) lower than in the 
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shMock cells. (B) Immunoblotting analysis shows that the SIPA1 protein levels in the 
shSIPA1 cells also are decreased markedly compared with the shMock cells. 
 
Fig. 4. Cellular functional analyses with SIPA1 knockdown cells (A) A cellular 
proliferation assay of shMock and shSIPA1 cells (HSC-3 and HSC-4 derived 
transfectants) was performed to determine the effect of shSIPA1 on cellular proliferation. 
shMock and shSIPA1 cells are seeded in 6-cm dishes at a density of 1×104 viable 
cells/well. The shSIPA1 cells show similar cellular growth compared with the shMock 
cells. The results are expressed as the means ± SEM of values from three assays (✽P<0.05, 
Student’s t-test). (B) An invasion assay of the shMock and shSIPA1 cells (HSC-3 and 
HSC-4 derived transfectants) was examined to evaluate the effect of SIPA1 knockdown 
cells on invasiveness. The number of shSIPA1 cells penetrating through the micro pores is 
decreased significantly (✽P<0.05, Student’s t-test) compared with the control cells 
(shMock). The mean value was calculated from data obtained from three separate 
chambers. (C) A migration assay of shMock and shSIPA1 cells (HSC-3 and HSC-4-
derived transfectants) was examined to evaluate the effect of SIPA1 knockdown on 
migration. Uniform wounds are made in confluent cultures of the shSIPA1 and shMock 
cells and the extent of closure is monitored visually at every 12 hours for 24 hours. The 
mean value is calculated from data obtained from three separate chambers. The wound 
area is decreased obviously (✽P<0.05, Student’s t-test) in the culture of shMock cells after 
24 hours, whereas a gap remains in the shSIPA1 cells. (D) An adhesion assay of the 
shMock and shSIPA1 cells (HSC-3 and HSC-4-derived transfectants) was examined to 
evaluate the effect of SIPA1 knockdown on adhesion ability. The shSIPA1 and shMock 
cells are seeded on collagen I-coated 96-well plates at a density of 2 ×104 cells/well and 
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allowed to adhere for 1 hour. After crystal violet staining, the numbers of adherent stained 
cells are counted using a light microscope at ×100 magnification. The cellular adhesion of 
shSIPA1 cells is increased markedly (✽P<0.05, Student’s t-test) compared with the 
shMock cells.  
 
Fig. 5. BRD4 expression in SIPA1 knockdown cells. Western blot analysis shows the 
expression levels of SIPA1 and BRD4 protein in the nuclear and cytosolic fractions of the 
shMock and shSIPA1 cells. The BRD4 protein expression in the nuclear fraction of the 
shSIPA1 cells is obviously (✽P<0.05, Student’s t-test) greater than that in the shMock 
cells. 
 
Fig. 6. ITGB1 and MMP7 expression levels in SIPA1 knockdown cells. qRT-PCR and 
Western blot analysis show the expression levels of ITGB1and MMP7 in the shMock and 
shSIPA1 cells (HSC-3 and HSC-4-derived transfectants). (A) The expression of ITGB1 
mRNA in shSIPA1 cells is markedly (✽P<0.05, Student’s t-test) higher than that in the 
shMock cells. The data are expressed as the mean ± SEM of triplicate results. (B) ITGB1 
protein levels in the shSIPA1 cells also are markedly increased compared with the shMock 
cells by Western blot analysis. (C) Analysis of the expression of MMP7 mRNA in the 
shMock and shSIPA1 cells (HSC-3 and HSC-4 derived transfectants) shows that there is 
significantly (✽P<0.05, Student’s t-test) less MMP7 mRNA in the shSIPA1 cells compared 
with that in the shMock cells. (D) In the shSIPA1 cells, the expression of MMP7 protein is 
clearly decreased compared with the shMock cells.  
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Table 1. Correlation between SIPA1 expression and clinical classification in OSCCs.  
Clinical classification  
Results of immunostaining 
No. patients 
 
  
 
Total 
SIPA1 
negative 
SIPA1 
positive 
P value 
Age at surgery (years) 
    
   < 70 61 19 42 
0.08 
b
 
   ≧70 44  20 24 
   
    
     
Gender 
    
  Male 63 20 43 
0.16 
b
 
  Female 42 19 23 
     
T-primary tumor 
    
  T1+T2 56 22 34 
 0.193
 b 
  T3+T4 49 17 32 
   
 
  
  
   
 
  
  
    
N-regional lymph node 
   
  Negative 65 29 36 
 0.043
 b*
 
  Positive 40  10 30 
     
Stage 
    
  I+ II 43 18 25 
0.193
 b
 
  III+ IV 62 21 41 
  
  
  
     
     
Vascular invasion 
    
Negative 88 36 52 
0.069 
b
 
Positive 17  3 14 
     
Histopathologic type     
  Well 69 23 46 
0.512 
c
   Moderately 33 15 18 
  Poorly 3  1  2 
     
Tumoral site 
    
  Gingiva 42 13 29 
0.53
a
 
  Tongue 35 15 20 
  Buccal mucosa 19  6  13 
Oral floor 3  1  2 
  Soft palate 6  4  2 
(*)Asterisks indicate significance. 
aχ2 test. bFisher’s exact test.cMann-Whitney U-test. 
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